EUVIMEDEUVIMED entdecken
Crossref

72909 Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment

Christopher E.M. Griffiths, Antonio Costanzo, Kim A. Papp, David Rosmarin, Luis Puig, Andrew Blauvelt, Krista Wixted, José M. López Pinto, Jérémy Lambert, Rhys Warham, George Han

Journal of the American Academy of Dermatology · 2026-07 · 95 (1) · AB80

DOI: 10.1016/j.jaad.2026.04.331 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-07. Verfasst von Christopher E.M. Griffiths und 10 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Griffiths, C. E., Costanzo, A., Papp, K. A., Rosmarin, D., Puig, L., Blauvelt, A., Wixted, K., Pinto, J. M. L., Lambert, J., Warham, R., & Han, G. (2026). 72909 Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment. Journal of the American Academy of Dermatology, 95(1), AB80. https://doi.org/10.1016/j.jaad.2026.04.331

Vancouver

Griffiths CE, Costanzo A, Papp KA, Rosmarin D, Puig L, Blauvelt A, et al. 72909 Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment. Journal of the American Academy of Dermatology. 2026;95(1):AB80. doi:10.1016/j.jaad.2026.04.331

BibTeX
@article{Griffiths2026,
  author = {Griffiths, Christopher E.M. and Costanzo, Antonio and Papp, Kim A. and Rosmarin, David and Puig, Luis and Blauvelt, Andrew and Wixted, Krista and Pinto, José M. López and Lambert, Jérémy and Warham, Rhys and Han, George},
  title = {72909 Bimekizumab durability of response through 4 years in patients with plaque psoriasis who stopped and re-started treatment},
  journal = {Journal of the American Academy of Dermatology},
  year = {2026},
  volume = {95},
  number = {1},
  pages = {AB80},
  doi = {10.1016/j.jaad.2026.04.331}
}
Kostenlos starten →